Cencora beats quarterly profit estimates on strong demand for specialty medicines

Core Insights - Cencora exceeded Wall Street profit estimates for the first quarter, driven by strong demand for specialty medicines and GLP-1 therapies [1] Company Performance - Cencora reported a profit that surpassed analyst expectations, indicating robust financial health and operational efficiency in the current market [1] Industry Trends - The sustained demand for specialty medicines and GLP-1 therapies highlights a growing trend in the pharmaceutical industry, suggesting potential for continued growth in these segments [1]